Scarica l'app Stockscreener
34.56
1.98%
-0.705
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
HC Wainwright Boosts Earnings Estimates for Tyra Biosciences - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year HighHere's Why - MarketBeat
Tyra Bioscience Raises $126 Million in Block Share Sale - TipRanks
Tyra Biosciences announces $126 million stock sale in block transaction By Investing.com - Investing.com Australia
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Tyra Biosciences has reached an agreement to privately issue 4 million common shares to a major investment management firm. - Bitget
Tyra Biosciences agreed to issue 4 million shares at $31.50 per share to a large investment management firmSEC filing - marketscreener.com
Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management FirmSEC Filing - TradingView
Tyra Bios to sell 4.0M shares at $31.50 in $126M ATM block transaction - TradingView
Tyra Biosciences stock reaches all-time high at 35.75 USD - Investing.com
Tyra Biosciences stock reaches all-time high at 35.75 USD By Investing.com - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.4%Here's What Happened - MarketBeat
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView
TYRA: Oral dabogratinib targets blockbuster opportunities in UTUC, NMIBC, and achondroplasia - TradingView
Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative? - Yahoo Finance
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
TYRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tyra Biosciences Q4 Loss Widens - marketscreener.com
Tyra Biosciences 10-K: Net loss $119.95M, EPS $(2.01) - TradingView
Tyra Biosciences (NASDAQ: TYRA) maps FGFR oncology and achondroplasia pipeline - Stock Titan
Tyra Biosciences (Nasdaq: TYRA) boosts R&D and outlines 2026 trial catalysts - Stock Titan
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - Yahoo Finance
TYRATyra Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan
Nasdaq Moves: What are the risks of holding Tyra Biosciences Inc2025 Market WrapUp & Stepwise Trade Execution Plans - baoquankhu1.vn
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Swings: Is Tyra Biosciences Inc stock undervalued right nowMarket Risk Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
CEO Change: Is Tyra Biosciences Inc stock undervalued right nowPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Tyra Biosciences (TYRA) Valuation Under Review After ASCO Catalysts And Positive Analyst Attention - Sahm
TYRA Should I Buy - Intellectia AI
Tyra Biosciences, Inc. (TYRA) Stock Analysis: 48.56% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
(TYRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
TYRA: Phase II trials for dabogratinib target NMIBC, UTUC, and achondroplasia, with key data due this year - TradingView
TYRA: FGFR3-targeted trials advance in NMIBC, achondroplasia, and UTUC, with key data expected this year - TradingView
Tyra Biosciences (TYRA) Price Target Increased by 14.97% to 48.96 - Nasdaq
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Tyra Biosciences stock hits all-time high at 34.0 USD - Investing.com India
Stock Report: What are analysts price targets for Portage Biotech IncJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Raymond James Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $55 - 富途牛牛
Tyra Biosciences stock hits all-time high at 34.0 USD By Investing.com - Investing.com South Africa
Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month HighWhat's Next? - MarketBeat
Cantor Fitzgerald Initiates Tyra Bioscience at Overweight - marketscreener.com
POM Investors Have Opportunity to Lead PomDoctor Ltd. Securities Fraud Lawsuit - Weekly Voice
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium - PR Newswire
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - The Motley Fool
Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Biotech With 57% Potential Upside - DirectorsTalk Interviews
Farallon-affiliated holders disclose stakes in Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Tyra Biosciences to Participate in Upcoming Investor Conferences - marketscreener.com
Biotech Tyra Biosciences lines up five investor events from Boston to Miami - Stock Titan
June Brings on Some Huge Insider Buying - AOL.com
Tyra Biosciences patents new FGFR inhibitors - BioWorld MedTech
Signal Recap: Can Open Text Corporation sustain its profitabilityEarnings Growth Report & Smart Money Movement Alerts - baoquankhu1.vn
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛
Weekly Earnings: Is Tyra Biosciences Inc exposed to currency risks2025 Volatility Report & Consistent Income Trade Ideas - baoquankhu1.vn
Price-Driven Insight from (TYRA) for Rule-Based Strategy - Stock Traders Daily
RSI Check: Is Tyra Biosciences Inc a turnaround storyWeekly Trading Summary & Intraday High Probability Alerts - baoquankhu1.vn
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences price target raised to $53 from $37 at Wedbush - Yahoo Finance
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
DKAs Burden The Clinical and Economic Impact - William Blair
Is Tyra Biosciences Inc.’s ROE strong enoughMarket Movement Recap & High Return Trade Guides - mfd.ru
Tyra Biosciences Advances TYRA-300 Bladder Cancer Trial: What Investors Should Watch - TipRanks
Wedbush Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $53.00 - MarketBeat
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $53 - 富途牛牛
4.07%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):